Latest Earnings Results: Q3 '26
Estimated EPS
$1.55
Reported EPS
$1.98
Surprise
+27.46%
Estimated Rev
$15.18B
Reported Rev
$15.87B
Surprise
+4.55%
• Reported GAAP EPS of $2.01 up 17.54% YoY • Reported revenue of $17.25B up 11.64% YoY • Sanofi upgraded FY 2026 guidance: sales are expected to grow by a low-teens percentage at CER, and business EPS at CER is expected to grow by a mid-teens percentage.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.91 | -- | -- | N/A |
Q3 '26 | $1.55 | $1.98 | 27.46% | BEAT |
Q2 '26 | $1.07 | $1.20 | 11.83% | BEAT |
Q1 '26 | $1.04 | $1.10 | 6.21% | BEAT |
Q4 '25 | $0.84 | $0.91 | 8.38% | BEAT |